chapter 44 references - eular 44.pdfchapter 44 references . abe a, ishikawa h, murasawa a, et al....

EULAR Secretariat | Seestrasse 240 | 8802 Kilchberg | Switzerland T: +41 44 716 30 30 | F: +41 44 716 30 39 M: [email protected] | W: www.eular.org

1

Chapter 44 References

Abe A, Ishikawa H, Murasawa A, et al. Disease activity and the course of elbow joint deterioration over 10 years in the patients with early rheumatoid arthritis. Clin Rheumatol 2008;27:867–72.

Akkoc Y, Karatepe AG, Akar S, et al. A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int 2005;25:280–4.

Aktan S, Ilknur T, Akin C, et al. Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol 2007;32:141–4.

*Aletaha D, Ward MM, Machold KP. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625–36.

Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67:1360–4.

Aletaha D, Machold KP, Nell VP, et al. The perception of rheumatoid arthritis core set measures by rheumatologists: results of a survey. Rheumatology (Oxford) 2006;45:1133–9.

Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806.

Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784–92.

Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(suppl):S100–8.

Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol 2006;24(suppl):S45–51.

Aletaha D. Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind? Arthritis Res Ther 2006;8:102.

Amor B, Dougados M, Mijiyawa M. Criteres de classification des spondylarthropathies [in French]. Rev Rhum Mal Osteoartic 1990;57:85–9.

Anderson J, Sayles H, Curtis JR, et al. Converting Modified Health Assessment Questionnaire (HAQ), Multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2010;62:1481–8.

Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876–86.

Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150–7.


2

Arya V, Malaviyab AN, Raja RR. CDAI (Clinical Disease Activity Index) in rheumatoid arthritis: cut-off values for classification into different grades of disease activity. Indian J Rheumatol 2007;2:91–4.

Ashcroft DM, Wan Po AL, Williams HC, et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141:185–91.

Athale N, Sturley A, Skoczen S, et al. A web-compatible instrument for measuring self-reported disease activity in arthritis. J Rheumatol 2004;31:223–8.

Atzeni F, Antivalle M, Pallavicini FB, et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 2009;8:431–7.

Augustin M, Ogilvie A. Methods of outcomes measurement in nail psoriasis. Dermatology 2010;221(suppl):23–8.

Averns HL, Oxtoby J, Taylor HG, et al. Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 1996;25:138–42.

Baker PR, Groh JD, Kraag GR, et al. Impact of patient with patient interaction on perceived rheumatoid arthritis overall disease status. Scand J Rheumatol 1996;25:207–12.

Balint PV, Kane D, Wilson H, et al. Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis 2002;61:905–10.

Balsa A, Carmona L, Gonzalez-Alvaro I, et al. Value of Disease Activity Score 28 (DAS28) and DAS28–3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004;31:40–6.

Balsa A, de Miguel E, Castillo C, et al. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology (Oxford) 2010;49:683–90.

Barton JL. Systematic review and metaanalysis of patient self-report versus trained assessor joint counts in rheumatoid arthritis. J Rheumatol 2009;36:2635–41.

Belza BL, Henke CJ, Yelin EH, et al. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993;42:93–9.

Bennett P, Burch T. Population studies of the rheumatic diseases. Amsterdam, The Netherlands: Excerpta Medica Foundation, 1968:456–7.

Berglin E, Lorentzon R, Nordmark L, et al. Predictors of radiological progression and changes in hand bone density in early rheumatoid arthritis. Rheumatology (Oxford) 2003;42:268–75.

Berth-Jones J, Thompson J, Papp K. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol 2008;159:407–12.

Blackmore MG, Gladman DD, Husted J, et al. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995;22:886–93.

Bodur H, Ataman S, Rezvani A, et al. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res 2011;20:543–9.


3

Bonisch A, Ehlebracht-Konig I. The BASDAI-D—an instrument to defining disease status in ankylosing spondylitis and related diseases [in German]. Z Rheumatol 2003;62:251–63.

Boonen A, de Vet H, van der Heijde D, et al. Work status and its determinants among patients with ankylosing spondylitis: a systematic literature review. J Rheumatol 2001;28:1056–62.

Brandt J, Listing J, Sieper J, et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438–44.

Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346–52.

Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667–75.

Brandt J, Westhoff G, Rudwaleit M, et al. Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany [in German]. Z Rheumatol 2003;62:264–73.

Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316–20.

Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187–93.

Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817–24.

Buskila D, Langevitz P, Gladman DD, et al. Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis. J Rheumatol 1992;19:1115–9.

Calin A, Jones SD, Garrett SL, et al. Bath Ankylosing Spondylitis Functional Index. Br J Rheumatol 1995;34:793–4.

Calin A, Porta J, Fries JF, et al. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977;237:2613–4.

Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281–5.

Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281–5.

Calin A, Nakache JP, Gueguen A, et al. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 1999;38:878–82.

Callahan LF, Smith WJ, Pincus T. Self-report questionnaires in five rheumatic diseases: comparisons of health status constructs and associations with formal education level. Arthritis Care Res 1989;2:122–31.


4

Calvo FA, Calvo A, Berrocal A, et al. Self-administered joint counts in rheumatoid arthritis: comparison with standard joint counts. J Rheumatol 1999;26:536–9.

Cantini F, Niccoli L, Nannini C, et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford) 2008;47:872–6.

Cardiel MH, Londono JD, Gutierrez E, et al. Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies. Clin Exp Rheumatol 2003;21:451–8.

Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859–66.

Cassell SE, Bieber JD, Rich P, et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007;34:123–9.

Castrejon I, Silva-Fernandez L, Bombardier C, et al. Clinical composite measures of disease activity for diagnosis and followup of undifferentiated peripheral inflammatory arthritis: a systematic review. J Rheumatol Suppl 2011;87:48–53.

Cauli A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011;38:898–903.

Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528–38.

Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Evanston (IL):Center on Outcomes, Research, and Education, Evanston Northwestern Healthcare and Northwestern University; 1997.

Chandran V, Bhella S, Schentag C, et al. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007;66:936–9.

Chandran V, Gottlieb A, Cook RJ, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum 2009;61:1235–42.

Choy EH, Khoshaba B, Cooper D, et al. Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice. Arthritis Rheum 2008;59:192–9.

Claudepierre P, Sibilia J, Goupille P, et al. Evaluation of a French version of the Bath Ankylosing Spondylitis Disease Activity Index in patients with spondyloarthropathy. J Rheumatol 1997;24:1954–8.

Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996;39:2013–20.

*Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48–53.


5

Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 2010;62:970–6.

Coates LC, Helliwell PS. Disease measurement: enthesitis, skin, nails, spine and dactylitis. Best Pract Res Clin Rheumatol 2010;24:659–70.

Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010;62:965–9.

Cohen JD, Cunin P, Farrenq V, et al. Estimation of the Bath Ankylosing Spondylitis Disease Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathies. J Rheumatol 2006;33:79–81.

Creemers MC, Franssen MJ, van’t Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127–9.

Daltroy LH, Larson MG, Roberts NW, et al. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 1990;17:946–50.

Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230–6.

Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218–27.

Dougados M, Behier JM, Jolchine I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180–5.

Dougados M, Gueguen A, Nakache JP, et al. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 1988;15:302–7.

Dougados M, Jousse-Joulin S, Mistretta F, et al. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. Ann Rheum Dis 2010;69:828–33.

Dougados M, Luo MP, Maksymowych WP, et al, for the Atlas Study Group. Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial. Arthritis Rheum 2008;59:553–60.

Doward LC, McKenna SP, Meads DM, et al. Translation and validation of non-English versions of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire. Health Qual Life Outcomes 2007;5:7.

Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20–6.

Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20–6.

Drossaers-Bakker KW, de Buck M, van Zeben D, et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42:1854–60.


6

Duruoz T, Doward LC, Cerrahoglu L, et al. Translation and validation of the Turkish version of the ankylosing spondylitis quality of life (ASQoL) Questionnaire [abstract]. Ann Rheum Dis 2008;67(suppl II):623.

Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105–21.

Eberl G, Studnicka-Benke A, Hitzelhammer H, et al. Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology (Oxford) 2000;39:148–55.

Eder L, Chandran V, Shen H, et al. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 2010;69:2160–4.

Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208–13.

El Miedany Y, Youssef S, Mehanna A, et al. Defining disease status in ankylosing spondylitis: validation and cross-cultural adaptation of the Arabic Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Bath Ankylosing Spondylitis Global score (BASG). Clin Rheumatol 2008;27:605–12.

Englbrecht M, Wang Y, Ronneberger M, et al. Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives. Arthritis Care Res (Hoboken) 2010;62:977–83.

Eyres S, Tennant A, Kay L, et al. Measuring disability in ankylosing spondylitis: comparison of Bath Ankylosing Spondylitis Functional Index with revised Leeds Disability Questionnaire. J Rheumatol 2002;29:979–86.

Feldman SR, Fleischer AB Jr, Reboussin DM, et al. The self-administered Psoriasis Area and Severity Index is valid and reliable. J Invest Dermatol 1996;106:183–6

*Felson DT, Anderson JJ, Boers M. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:27–35.

Felson DT, Anderson JJ, Boers M, et al, for the Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729–40.

Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729–40.

*Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.

Fernandez-Sueiro JL, Willisch A, Pertega-Diaz S, et al. Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis. Arthritis Rheum 2009;61:386–92.

Ferraccioli G, Bartoli E, Salaffi F, et al. The Chronic Arthritis Systemic Index: a nomogram to assess the activity and severity of chronic arthritis [letter]. Arthritis Rheum 1993;36:1180–1.

Ferraccioli GF, Salaffi F, Troise-Rioda W, et al. The Chronic Arthritis Systemic Index (CASI). Clin Exp Rheumatol 1994;12:241–7.


7

Figueroa F, Braun-Moscovici Y, Khanna D, et al. Patient self-administered joint tenderness counts in rheumatoid arthritis are reliable and responsive to changes in disease activity. J Rheumatol 2007;34:54–6.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–6.

FitzGerald O, Helliwell P, Mumtaz A, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA dataset [abstract]. Arthritis Rheum 2010;62(suppl):S214.

Fitzpatrick R, Newman S, Lamb R, et al. A comparison of measures of health status in rheumatoid arthritis. Br J Rheumatol 1989;28:201–6.

Fransen J, Stucki G, van Riel PL. Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum 2003;49(suppl):S214–24.

Fransen J, Antoni C, Mease PJ, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373–8.

Fransen J, Forster A, Uebelhart D, et al. Reliability and responsiveness of the RADAI, a self-assessed rheumatoid arthritis disease activity index [abstract]. Ann Rheum Dis 2001;60(suppl):345.

Fransen J, Hauselmann H, Michel BA, et al. Responsiveness of the self-assessed Rheumatoid Arthritis Disease Activity Index to a flare of disease activity. Arthritis Rheum 2001;44:53–60.

Fransen J, Langenegger T, Michel BA, et al. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford) 2000;39:321–7.

Fransen J, Stucki G, van Riel PL. Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum 2003;49(suppl):S214–24.

Fransen J, Uebelhart D, Stucki G, et al. The ICIDH-2 as a framework for the assessment of functioning and disability in rheumatoid arthritis. Ann Rheum Dis 2002;61:225–31.

Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol 2006;24(suppl):S29–32.

Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23(suppl):S93–9.

Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157:238–44.

Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.

Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum 1994;37:470–5.

Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2011;70(suppl):i2–36.


8

Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.

Gisondi P, Tinazzi I, El-Dalati G, et al. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis 2008;67:26–30.

Gladman D, Inman R, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise: the INSPIRE study. I. Assessment of spinal measures. J Rheumatol 2007;34:1733–9.

*Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167–70.

Gladman DD, Chandran V. Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology (Oxford) 2011;50:25–31.

Gladman DD, Helliwell P, Mease PJ, et al. Assessment of patients with psoriatic arthritis: a review of currently available measures [review]. Arthritis Rheum 2004;50:24–35.

Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise: the INSPIRE study. II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007;34:1740–5.

Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167–70.

Gladman DD, Psaradellis F, Illouz O, et al. Evaluation of response using the psoriatic arthritis joint activity index scoring tool in patients treated with adalimumab: post hoc analysis of the ACCLAIM study [abstract]. J Rheumatol 2009;38:2571.

Gladman DD, Tom BD, Mease PJ, et al. Informing response criteria for psoriatic arthritis. I. Discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol 2010;37:1892–7.

Gladman DD, Tom BD, Mease PJ, et al. Informing response criteria for psoriatic arthritis (PsA). II. Further considerations and a proposal: the PsA joint activity index. J Rheumatol 2010;37:2559–65.

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010;69:65–9.

Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. 2002;346:1349–56.

Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263–9.

Hanly JG, Mosher D, Sutton E, et al. Self-assessment of disease activity by patients with rheumatoid arthritis. J Rheumatol 1996;23:1531–8.

Harrington JT. The uses of disease activity scoring and the physician global assessment of disease activity for managing rheumatoid arthritis in rheumatology practice. J Rheumatol 2009;36:925–9.

Haywood KL, Garratt AM, Dawes PT. Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford) 2005;44:577–86.


9

Haywood KL, Garratt M, Jordan K, et al. Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 2002;41:1295–302.

Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686–91.

Healy PJ, Helliwell PS. Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol 2007;34:1302–6.

Healy PJ, Helliwell PS. Psoriatic arthritis quality of life instrument: an assessment of sensitivity and response to change. J Rheumatol 2008;35:1359–61.

Heikkila S, Viitanen JV, Kautiainen H, et al. Does improved spinal mobility correlate with functional changes in spondyloarthropathy after short-term physical therapy? J Rheumatol 2000;27:2942–4.

Heikkila S, Viitanen JV, Kautiainen H, et al. Functional long-term changes in patients with spondylarthropathy. Clin Rheumatol 2002;21:119–22.

Helliwell PS, Firth J, Ibrahim GH, et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;32:1745–50.

Hensor EM, Emery P, Bingham SJ, et al, for the YEAR Consortium. Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced? Rheumatology (Oxford) 2010;49:1521–9.

Hernandez-Cruz B, Cardiel MH. Intra-observer reliability of commonly used outcome measures in rheumatoid arthritis. Clin Exp Rheumatol 1998;16:459–62.

Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127–32.

Hidding A, van der Linden S, Gielen X, et al. Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial. Arthritis Care Res 1994;7:90–6.

Hidding A, van der Linden S. Factors related to change in global health after group physical therapy in ankylosing spondylitis. Clin Rheumatol 1995;14:347–51.

Husni ME, Mease PJ. Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep 2010;12:281–7.

Husted J, Gladman DD, Farewell VT, et al. Validation of the revised and expanded version of the Arthritis Impact Measurement Scales for patients with psoriatic arthritis. J Rheumatol 1996;23:1015–9.

Husted J, Gladman DD, Long JA, et al. Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. J Rheumatol 1996;23:1932–7.

Husted JA, Gladman DD, Farewell VT, et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997;24:511–7.

Husted JA, Gladman DD, Long JA, et al. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Dermatol 1995;13:439–43.


10

Husted JA, Tom BD, Farewell VT, et al. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum 2007;56:840–9.

Inoue E, Yamanaka H, Hara M, et al. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28 C-reactive protein threshold values. Ann Rheum Dis 2007;66:407–9.

Jauregui E, Conner-Spady B, Russell AS, et al. Clinimetric evaluation of the Bath Ankylosing Spondylitis Metrology Index in a controlled trial of pamidronate therapy. J Rheumatol 2004;31:2422–8.

Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694–8.

Jenks K, Treharne GJ, Garcia J, et al. The ankylosing spondylitis quality of life questionnaire: validation in a New Zealand cohort. Int J Rheum Dis 2010;13:361–6.

Jones SD, Porter J, Garrett SL, et al. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 1995;22:1609.

Jones SD, Calin A, Steiner A. An update on the Bath Ankylosing Spondylitis Disease Activity and Functional Indices (BASDAI, BASFI): excellent Cronbach's alpha scores. J Rheumatol 1996;23:407.

Jones SD, Porter J, Garrett SL, et al. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI) [letter]. J Rheumatol 1995;22:1609.

Jones SD, Steiner A, Garrett SL, et al. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996;35:66–71.

Kane D. The role of ultrasound in the diagnosis and management of psoriatic arthritis. Curr Rheumatol Rep 2005;7:319–24.

Karatepe AG, Akkoc Y, Akar S, et al. The Turkish versions of the Bath Ankylosing Spondylitis and Dougados Functional Indices: reliability and validity. Rheumatol Int 2005;25:612–8.

Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four–week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976–86.

Kawashiri SY, Kawakami A, Iwamoto N, et al. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis. Rheumatology (Oxford) 2010;50:962–5.

Kennedy LG, Edmunds L, Calin A. The natural history of ankylosing spondylitis. Does it burn out? J Rheumatol 1993;20:688–92.

Khan NA, Yazici Y, Calvo-Alen J, et al. Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. J Rheumatol 2009;36:2435–42.

Kiltz U1, van der Heijde D, Boonen A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 2014 Jan 7. doi:10.1136/annrheumdis-2013-203967. [Epub ahead of print].


11

Kirwan JR, Newman S, Tugwell PS, et al. Patient perspective on outcomes in rheumatology: a position paper for OMERACT 9. J Rheumatol 2009;36:2067–70.

Klinkhoff AV, Bellamy N, Bombardier C, et al. An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol 1988;15:492–4.

Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478–87.

Krishnan E, Sokka T, Hakkinen A, et al. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004;50:953–60.

Krueger GG. New method being developed for assessing psoriasis. National Psoriasis Foundation Forum 1999;5:4–5.

Krupp LB, LaRocca NG, Muir-Nash J, et al. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121–3.

Kuhlow H, Fransen J, Ewert T, et al. Factors explaining limitations in activities and restrictions in participation in rheumatoid arthritis. Eur J Phys Rehabil Med 2010;46:169–77.

Kurwa HA, Finlay AY. Dermatology in-patient management greatly improves life quality. Br J Dermatol 1995;133:575–8.

Kvien TK, Heiberg, Lie E, Kaufmann C, et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23(suppl 39):S188–94.

Kwok T, Pope JE. Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol 2010;37:1024–8.

Landewe R, Dougados M, Mielants H, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009;68:863–7.

Landewe R, van der Heijde D, van der Linden S, et al. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006;65:637–41.

Landewe RB, Hermann KG, van der Heijde DM, et al. Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. J Rheumatol 2005;32:2050–5.

Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol 2004;51:563–9.

Lassere MN, van der Heijde D, Johnson KR, et al. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol 2001;28:892–903.

Ledingham J, Deighton C, for the British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update on the British Society for Rheumatology guidelines for prescribing


12

TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005;44:157–63.

Leeb BF, Haindl PM, Maktari A, et al. Patient-centered rheumatoid arthritis disease activity assessment by a modified RADAI. J Rheumatol 2008;35:1294–9.

Leeb BF, Sautner J, Leeb BA, et al. Lack of agreement between patients and physicians perspectives of rheumatoid arthritis disease activity changes. Scand J Rheumatol 2006;35:441–6.

Leeb BF, Sautner J, Mai HT, et al. A comparison of patient questionnaires and composite indexes in routine care of rheumatoid arthritis patients. Joint Bone Spine 2009;76:658–64.

Leigh JP, Fries JF, Parikh N. Severity of disability and duration of disease in rheumatoid arthritis. J Rheumatol 1992;19:1906–11.

Leung YY, Tam LS, Kun EW, et al. Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses. J Rheumatol 2008;35:1613–21.

Levy G, Cheetham C, Cheatwood A, et al. Validation of patient-reported joint counts in rheumatoid arthritis and the role of training. J Rheumatol 2007;34:1261–5.

Lindsay K, Ibrahim G, Sokoll K, et al. The composite DAS score is impractical to use in daily practice: evidence that physicians use the objective component of the DAS in decision making. J Clin Rheumatol 2009;15:223–5.

Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low: results from RABBIT, the German biologics register. Arthritis Res Ther 2006;8:R66.

Long CC, Finlay AY, Averill RW. The rule of hand: 4 hand areas = 2 FTU = 1 g. Arch Dermatol 1992;128:1129–30.

Long CC, Finlay AY. The finger-tip unit: a new practical measure. Clin Exp Dermatol 1991;16:444–7.

Louden BA, Pearce DJ, Lang W, et al. A simplified psoriasis area severity index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J 2004;10:7.

Lovas K, Geher P, Whalley D, McKenna S, Meads D, Kalo Z. Hungarian adaptation of a disease-specific quality-of-life questionnaire in patients with ankylosing spondylitis [in Hungarian]. Orv Hetil 2002;143:1893–7.

Lubrano E, Marchesoni A, Olivieri I, et al. Psoriatic Arthritis Spondylitis Radiology Index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis. J Rheumatol 2009;36:1006–11.

Lubrano E, Marchesoni A, Olivieri I, et al. The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. Clin Exp Rheumatol 2009;27:977–80.

Lukas C, Braun J, van der Heijde D, et al. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol 2007;34:862–70.

Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18–24.


13

Macedo A, Oakley S, Gullick N, et al. An examination of work instability, functional impairment, and disease activity in employed patients with rheumatoid arthritis. J Rheumatol 2009;36:225–30.

Machado P, van der Heijde D. How to measure disease activity in axial spondyloarthritis? Curr Opin Rheumatol 2011;23:339–45.

Machado P, Landewe R, Braun J, et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010;69:1465–70.

*Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47–53.

*Machado P, van der Heijde D. How to measure disease activity in axial spondyloarthritis? Curr Opin Rheumatol 2011;23:339–45.

Machado PM, Landewe RB, van der Heijde DM. Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10. J Rheumatol 2011;38:1502–6.

Machado P, Navarro-Compán V, Landewé R, et al. How to calculate the ASDAS if the conventional CRP is below the limit of detection or if using high sensitivity CRP? - An analysis in the DESIR cohort. Arthritis Rheumatol 2014 Oct 20. doi:10.1002/art.38921. [Epub ahead of print]

Madsen OR, Rytter A, Hansen LB, et al. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients. Clin Rheumatol 2010;29:849–54.

Makinen H, Kautiainen H, Hannonen P, et al. A new disease activity index for rheumatoid arthritis: Mean Overall Index for Rheumatoid Arthritis (MOI-RA). J Rheumatol 2008;35:1522–7.

Maksymowych WP, Mallon C, Morrow S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009;68:948–53.

Maksymowych WP, Richardson R, Mallon C, et al. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthritis Rheum 2007;57:133–9.

Mander M, Simpson JM, McLellan A, et al. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987;46:197–202.

Martin M, Kosinski M, Bjorner JB, Ware JE Jr, et al. Item response theory methods can improve the measurement of physical function by combining the modified health assessment questionnaire and the SF-36 physical function scale. Qual Life Res 2007;16:647–60.

Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63(suppl 11):S4–13.

McGonagle D, Lories RJ, Tan AL, et al. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007;56:2482–91.

McKenna SP, Doward LC, Whalley D, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004;63:162–9.


14

McQueen F, Lassere M, Bird P, et al. Developing a magnetic resonance imaging scoring system for peripheral psoriatic arthritis. J Rheumatol 2007;34:859–61.

Mease P, Antoni C, Gladman DD, et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64(suppl):ii49–54.

Mease P, Ganguly L, Wanke E, et al. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) group guidelines [abstract]. Ann Rheum Dis 2004;63(suppl):391.

Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939–48.

Mease P, van der Heijde D. Joint damage in psoriatic arthritis: how is it assessed and can it be prevented? Int J Adv Rheumatol 2006;4:38–48.

Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005;64(suppl):ii78–82.

Mease PJ, Gladman DD, Ritchlin CT, et al, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279–89.

Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385–90.

Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 2011;38:2461–5.

*Mease PJ. Measures of psoriatic arthritis. Arthritis Care Res. 2011;63(suppl 11):S64–85.

Mease PJ. Improving the routine management of rheumatoid arthritis: the value of tight control. J Rheumatol 2010;37:1570–8.

Mease PJ. Psoriatic arthritis: pharmacotherapy update. Curr Rheumatol Rep 2010;12:272–80.

Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis 2011;70(suppl):i77–84.

Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer 1999;85:1186–96.

Minnock P, Kirwan J, Veale D, et al. Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis. Clin Exp Rheumatol 2010;28:401–4.

Moncur C. Ankylosing spondylitis measures. Arthritis Care Res 2003;49(suppl):S197–209.

Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2010;70:272–7.

Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2010;70:272–7.


15

Nell-Duxneuner VP, Stamm TA, Machold KP, et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010;69:546–9.

Nichol MB, Margolies JE, Lippa E, et al. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996;10:644–53.

Nicolau G, Yogui MM, Vallochi TL, et al. Sources of discrepancy in patient and physician global assessments of rheumatoid arthritis disease activity. J Rheumatol 2004;31:1293–6.

*Østergaard M, Edmonds J, McQueen F. The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis 2005;64:i2–55.

*Østergaard M, McQueen F, Wiell C, et al. The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA hands. J Rheumatol 2009;36:1816–24.

Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies: core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system [published erratum appears in J Rheumatol 2004;31:198]. J Rheumatol 2003;30:1385–6.

Ozcan E, Yilmaz O, Tutoglu A, et al. Validity and reliability of the Turkish version of the Health Assessment Questionnaire for the Spondyloarthropathies. Rheumatol Int [E-pub ahead of print].

Parekh K, Taylor WJ. The Patient Activity Scale-II is a generic indicator of active disease in patients with rheumatic disorders. J Rheumatol 2010;37:1932–4.

Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 2005;32:80–5.

Pedersen SJ, Sorensen IJ, Garnero P, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 2011;70:1375–81.

Pedersen SJ, Sorensen IJ, Hermann KG, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010;69:1065–71.

Pham T, Landewe R, van der Linden S, et al. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis 2006;65:1620–5.

Pham T, van der Heijde DM, Pouchot J, et al. Development and validation of the French ASQoL questionnaire. Clin Exp Rheumatol 2010;28:379–85.

Pimentel-Santos FM, Santos H, Barcelos A, et al. Portuguese version of the Bath indices for ankylosing spondylitis patients: a cross-cultural adaptation and validation. Ann Rheum Dis 2010;69(suppl 3):697.

Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308–15.

Pincus T, Bergman M, Sokka T, et al. Visual analog scales in formats other than a 10 centimeter horizontal line to assess pain and other clinical data. J Rheumatol 2008;35:1550–8.


16

Pincus T, Bergman MJ, Yazici Y, et al. An index of only patient-reported outcome measures, Routine Assessment of Patient Index Data 3 (RAPID3), in two abatacept clinical trials: similar results to Disease Activity Score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 2008;47:345–9.

Pincus T, Callahan LF, Brooks RH, et al. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med 1989;110:259–66.

Pincus T, Sokka T. Can a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores be informative in patients with all rheumatic diseases? Best Pract Res Clin Rheumatol 2007;21:733–53.

Pincus T, Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol 2003;17:753–81.

Pincus T, Strand V, Koch G, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003;48:625–30.

Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly Health Assessment Questionnaire format. Arthritis Rheum 1999;42:2220–30.

Pincus T, Swearingen CJ, Bergman M, et al. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 2008;35:2136–47.

Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken) 2010;62:181–9.

Pincus T, Yazici Y, Bergman M, et al. A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative Routine Assessment of Patient Index Data (RAPID) scores on a Multidimensional Health Assessment Questionnaire (MDHAQ). Best Pract Res Clin Rheumatol 2007;21:789–804.

Pincus T, Yazici Y, Bergman M. A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10–20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. Best Pract Res Clin Rheumatol 2007;21:755–87.

Pincus T. A Multidimensional Health Assessment Questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care. Bull NYU Hosp Jt Dis 2007;65:150–60.

Prajs K, Flicinski J, Brzosko I, et al. Quality of life and activity of disease in patients with rheumatoid arthritis [in Polish]. Ann Acad Med Stetin 2006;52(suppl):39–43.

*Prevoo ML, van’t Hof MA, Kuper, HH. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.


17

Prevoo ML, van Riel PL, van't Hof MA, et al. Validity and reliability of joint indices: a longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol 1993;32:589–94.

Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.

Queiro R, Sarasqueta C, Belzunegui J, et al. Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease. Semin Arthritis Rheum 2002;31:413–8.

Radovits BJ, Fransen J, van Riel PL, et al. Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis. Ann Rheum Dis 2008;67:1127–31.

Reeve BB, Hays RD, Bjorner JB, et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care 2007;45(suppl):S22–31.

Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206–12.

Rintelen B, Haindl PM, Maktari A, et al. SDAI/CDAI levels in rheumatoid arthritis patients are highly dependent on patient's pain perception and gender. Scand J Rheumatol 2008;37:410–3.

Rintelen B, Haindl PM, Sautner J, et al. The Rheumatoid Arthritis Disease Activity Index-5 in daily use: proposal for disease activity categories. J Rheumatol 2009;36:918–24.

Rintelen B, Sautner J, Haindl P, et al. Comparison of three rheumatoid arthritis disease activity scores in clinical routine. Scand J Rheumatol 2009;7:1–7.

Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387–94.

Rohekar G, Pope J. Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. J Rheumatol 2009;36:2178–82.

Rudwaleit M, Jurik A-G, Hermann K-GA, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis – a consensual approach by the ASAS/OMERACT MRI Group. Ann Rheum Dis 2009;68:1520–7.

Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000–8.

Rudwaleit M, Metter A, Listing J, et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006;54:569–78.

Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004;63:535–43.

*Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777–83.

Ruof J, Sangha O, Stucki G. Comparative responsiveness of 3 functional indices in ankylosing spondylitis. J Rheumatol 1999;26:1959–63.


18

Ruof J, Sangha O, Stucki G. Evaluation of a German version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI). Z Rheumatol 1999;58:218–25.

Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010;12:R94.

Salaffi F, Peroni M, Ferraccioli GF. Discriminating ability of composite indices for measuring disease activity in rheumatoid arthritis: a comparison of the Chronic Arthritis Systemic Index, Disease Activity Score and Thompson's Articular Index. Rheumatology (Oxford) 2000;39:90–6.

Salaffi F, Stancati A, Silvestri A, et al. Validation of the Italian versions of the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Dougados Functional Index (DFI) in patients with ankylosing spondylitis [in Italian]. Reumatismo 2005;57:161–73.

Schentag C, Gladman D. Changes in fatigue in psoriatic arthritis: disease activity of fibromyalgia [abstract]. Arthritis Rheum 2002;46(suppl):S424.

Schentag CT, Cichon J, MacKinnon A, et al. Validation and normative data for the 0–10 point scale version of the fatigue severity scale (FSS) [abstract]. Arthritis Rheum 2000;43(suppl):S177.

Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441–7.

Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638–43.

Scott DL, Choy EH, Greeves A, et al. Standardising joint assessment in rheumatoid arthritis. Clin Rheumatol 1996;15:579–82.

Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094–108.

Scott J, Huskisson EC. Vertical or horizontal visual analogue scales. Ann Rheum Dis 1979;38:560.

Scott PJ, Huskisson EC. Measurement of functional capacity with visual analogue scales. Rheumatol Rehabil 1977;16:257–9.

Seror R, Tubach F, Baron G, et al. Measure of function in rheumatoid arthritis: individualized or classical scales? Ann Rheum Dis 2010;69:97–101.

Shaver TS, Anderson JD, Weidensaul DN, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008;35:1015–22.

Shinjo SK, Goncalves R, Kowalski S, et al. Brazilian-Portuguese version and applicability questionnaire of the mobility index for ankylosing spondylitis. Clinics (Sao Paulo) 2007;62:139–44.

Shinjo SK, Goncalves R, Kowalski S, et al. Brazilian-Portuguese version of the Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) in patients with ankylosing spondylitis: a translation, cross-cultural adaptation, and validation. Clin Rheumatol 2007;26:1254–8.

*Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2011;68(suppl II):ii1–44.

Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS). Ann Rheum Dis 2009;68:784–8.


19

Smets EM, Garssen B, Bonke B, et al. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315–25.

Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.

Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011;63:43–52.

Smolen JS, Aletaha D. What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 2006;24(suppl):S7–13.

Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244–57.

Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75.

Song IH, Carrasco-Fernandez J, Rudwaleit M, et al. The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis 2008;67:1535–40.

Soubrier M, Zerkak D, Gossec L, et al. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol 2006;33:1243–6.

Spoorenberg A, van der Heijde D, de Klerk E, et al. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol 1999;26:961–5.

Stamm TA, Nell V, Mathis M, et al. Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. Arthritis Rheum 2007;57:487–94.

Stone MA, Pomeroy E, Keat A, et al. Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration. Rheumatology (Oxford) 2008;47:1213–8.

Strand V, Cohen S, Crawford B, et al, for the Leflunomide Investigators Groups. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:640–7.

Stucki G, Liang MH, Stucki S, et al. A self-administered Rheumatoid Arthritis Disease Activity Index (RADAI) for epidemiologic research: psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995;38:795–8.

Stucki G, Stucki S, Bruhlmann P, et al. Ceiling effects of the Health Assessment Questionnaire and its modified version in some ambulatory rheumatoid arthritis patients. Ann Rheum Dis 1995;54:461–5.

Sturrock RD. Clinical utility of ultrasonography in spondyloarthropathies. Curr Rheumatol Rep 2009;11:317–20.

Taylor AL, Balakrishnan C, Calin A. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum 1998;41:1119–25.


20

Taylor W, Gladman D, Helliwell P, et al, and the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.

Taylor WJ, Harrison AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 2004;51:311–5.

Taylor WJ, McPherson KM. Using Rasch analysis to compare the psychometric properties of the Short Form 36 physical function score and the Health Assessment Questionnaire disability index in patients with psoriatic arthritis and rheumatoid arthritis. Arthritis Rheum 2007;57:723–9.

The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.

Thompson PW, Hart LE, Goldsmith CH, et al. Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. J Rheumatol 1991;18:661–5.

Tubach F, Pham T, Skomsvoll JF, et al. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis. Arthritis Rheum 2006;55:960–3.

Tzelepis GE, Kalliakosta G, Tzioufas AG, et al. Thoracoabdominal motion in ankylosing spondylitis: association with standardised clinical measures and response to therapy. Ann Rheum Dis 2009;68:966–71.

Uhlig T, Kvien TK, Pincus T. Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. Ann Rheum Dis 2009;68:972–5.

van Echteld I, Cieza A, Boonen A, et al. Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol 2006;33:2475–83.

van der Heijde D, Calin A, Dougados M, et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999;26:951–4.

van der Heijde D, Landewé R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008;67:489–93.

van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two–week, randomized, controlled study. Arthritis Rheum 2005;52:1205–15.

van der Heijde D, Kivitz A, Schiff MH, et al, for the Atlas Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136–46.

van der Heijde D, Landewe R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008;67:489–93.

van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811–8.


21

van der Heijde D, Sharp J, Wassenberg S, et al. Psoriatic arthritis imaging: a review of scoring methods. 2005;64(suppl):ii61–4.

van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905–8.

van der Heijde D. Quantification of radiological damage in inflammatory arthritis: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Best Pract Res Clin Rheumatol 2004;18:847–60.

*van der Heijde DM, van’t Hof M, van Riel PL. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol 1993;20:538–41.

van der Heijde DM, Revicki DA, Gooch KL, et al. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 2009;11:R124.

van der Heijde DM, van't Hof M, van Riel PL, et al. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol 1993;20:538–41.

van der Heijde DM, van't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916–20.

van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.

van Gestel AM, Prevoo ML, van’t Hof MA. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34–40.

van Gestel AM, Anderson JJ, van Riel PL, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999;26:705–11.

van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845–50.

*van Gestel AM, Prevoo ML, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34–40.

van Riel P, Van Gestel A, Scott D. EULAR handbook of clinical assessment in rheumatoid arthritis. Alpen an den Rijn (The Netherlands):Van Suiden Communications; 2000.

van Riel PL, Freundlich B, MacPeek D, et al. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 2008;67:1104–10.

van Tubergen A, Debats I, Ryser L, et al. Use of a numerical rating scale as an answer modality in ankylosing spondylitis–specific questionnaires. Arthritis Rheum 2002;47:242–8.


22

van Tubergen A, Landewe R, van der Heijde D, et al. Combined spa–exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001;45:430–8.

Verhoeven AC, Boers M, van Der Linden S. Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis. Ann Rheum Dis 2000;59:966–74.

Viitanen JV, Heikkila S. Functional changes in patients with spondylarthropathy: a controlled trial of the effects of short-term rehabilitation and 3-year follow-up. Rheumatol Int 2001;20:211–4.

Villaverde V, Balsa A, Cantalejo M, et al. Activity indices in rheumatoid arthritis. J Rheumatol 2000;27:2576–81.

Wagner E, Ammer K, Kolarz G, et al. Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years. Rheumatol Int 2007;27:1041–8.

Waldner A, Cronstedt H, Stenstrom CH. The Swedish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Scand J Rheumatol Suppl 1999;111:10–6.

Wanders A, Landewe R, Dougados M, et al. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005;64:988–94.

Wanders AJ, Landewe RB, Spoorenberg A, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004;50:2622–32.

Ward MM, Kuzis S. Validity and sensitivity to change of spondylitis-specific measures of functional disability. J Rheumatol 1999;26:121–7.

Ward MM. Clinical measures in rheumatoid arthritis: which are most useful in assessing patients? J Rheumatol 1994;21:17–27.

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.

Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.

Wei JC, Wong RH, Huang JH, et al. Evaluation of internal consistency and re-test reliability of Bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan. Clin Rheumatol 2007;26:1685–91.

Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954–60.

Wells GA, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016–24.

Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557–60.


23

Welsing PM, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009–17.

Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991;18:1290–7.

Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407–17.

Wolfe F, Kleinheksel SM, Cathey MA, et al. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988;15:1480–8.

Wolfe F, Michaud K, Pincus T, et al. The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti–tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005;52:3873–9.

Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS-II). J Rheumatol 2005;32:2410–5.

Wolfe F, Michaud K, Pincus T. Development and validation of the Health Assessment Questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum 2004;50:3296–305.

Wolfe F, Rasker JJ, Boers M, et al. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum 2007;57:935–42.

Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001;28:982–9.

Yazici Y, Bergman M, Pincus T. Time to score quantitative rheumatoid arthritis measures: 28-joint count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol 2008;35:603–9.

Yazici Y, Erkan D, Peterson MG, et al. Morning stiffness: how common is it and does it correlate with physician and patient global assessment of disease activity? [letter]. J Rheumatol 2001;28:1468–9.

Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63–74.

Zhao LK, Liao ZT, Li CH, et al. Evaluation of quality of life using ASQoL questionnaire in patients with ankylosing spondylitis in a Chinese population. Rheumatol Int 2007;27:605–11.

Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442–52.

Zochling J, Sieper J, van der Heijde D, et al. Development of a core set of domains for data collection in cohorts of patients with ankylosing spondylitis receiving anti-tumor necrosis factor-alpha therapy. J Rheumatol 2008;35:1079–82.

chapter 44 references - eular 44.pdfchapter 44 references . abe a, ishikawa h, murasawa a, et al....

Documents